Abstract
Background: Natural products are characterized by their chemical diversity and being a good source of a range of bioactive structures including antidiabetic compounds. Diabetes mellitus (DM) is considered a major worldwide health concern. Rational drug design has been widely accomplished, to discover and optimize innovative leads for different molecular targets of type 2 DM including α-glucosidase, PPARγ, DPP-IV, PTP1B, AR, GSK-3β, 11β-HSD1, GK, etc. Objective: This review illustrates the potential of natural products as a rich source of lead compounds for antidiabetic drug discovery with some examples of computational studies carried out to determine the possible molecular target, structure activity relationship, and further optimization chances. Conclusion: Natural products will remain an attractive source for researchers to explore their therapeutic potential against DM. Guided by the computational studies; systematic lead optimization via structural modifications will speed up the generation of potential new clinical candidates for the treatment of type 2 DM.
Keywords: Natural lead, Antidiabetic, Molecular docking, α-Glucosidase, Dipeptidyl peptidase IV, Peroxisome proliferatoractivated receptor gamma, Aldose reductase, Protein-tyrosine phosphatase 1B.
Current Topics in Medicinal Chemistry
Title:Exploring Natural Products as a Source for Antidiabetic Lead Compounds and Possible Lead Optimization
Volume: 16 Issue: 23
Author(s): Reema Abu Khalaf
Affiliation:
Keywords: Natural lead, Antidiabetic, Molecular docking, α-Glucosidase, Dipeptidyl peptidase IV, Peroxisome proliferatoractivated receptor gamma, Aldose reductase, Protein-tyrosine phosphatase 1B.
Abstract: Background: Natural products are characterized by their chemical diversity and being a good source of a range of bioactive structures including antidiabetic compounds. Diabetes mellitus (DM) is considered a major worldwide health concern. Rational drug design has been widely accomplished, to discover and optimize innovative leads for different molecular targets of type 2 DM including α-glucosidase, PPARγ, DPP-IV, PTP1B, AR, GSK-3β, 11β-HSD1, GK, etc. Objective: This review illustrates the potential of natural products as a rich source of lead compounds for antidiabetic drug discovery with some examples of computational studies carried out to determine the possible molecular target, structure activity relationship, and further optimization chances. Conclusion: Natural products will remain an attractive source for researchers to explore their therapeutic potential against DM. Guided by the computational studies; systematic lead optimization via structural modifications will speed up the generation of potential new clinical candidates for the treatment of type 2 DM.
Export Options
About this article
Cite this article as:
Khalaf Abu Reema, Exploring Natural Products as a Source for Antidiabetic Lead Compounds and Possible Lead Optimization, Current Topics in Medicinal Chemistry 2016; 16 (23) . https://dx.doi.org/10.2174/1568026616666160414123602
DOI https://dx.doi.org/10.2174/1568026616666160414123602 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential of Gentiana lutea for the Treatment of Obesity-associated Diseases
Current Pharmaceutical Design The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology L-/N-type Calcium Channel Blockers and Proteinuria
Current Hypertension Reviews Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Plasminogen Activator Inhibitor with Very Long Half-life (VLHL PAI-1) can Reduce Bleeding in PAI-1-deficient Patients
Cardiovascular & Hematological Disorders-Drug Targets Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Current Drug Targets Elevated Inflammatory Parameter Levels Negatively Impact Populations of Circulating Stem Cells (CD133+), Early Endothelial Progenitor Cells (CD133+/VEGFR2+), and Fibroblast Growth Factor in Stroke Patients
Current Neurovascular Research Safety of Vascular Endothelial and Hepatocyte Growth Factor Gene Therapy in Patients with Critical Limb Ischemia
Current Neurovascular Research Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease
Current Alzheimer Research Effect of Systemic Inflammation on the Function of Insulin and Glucose Metabolism in Rheumatoid Arthritis
Current Diabetes Reviews Dietary Intake in HIV-Infected Men with Lipodystrophy: Relationships with Body Composition, Visceral Fat, Lipid, Glucose and Adipokine Metabolism
Current HIV Research Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry The Role of Niacin in Lipid-lowering Treatment: Are we Aiming Too High?
Current Pharmaceutical Design Use of Biguanides and the Risk of Colorectal Cancer: A Register-Based Cohort Study
Current Drug Safety Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Age Matching Animal Models to Humans - Theoretical Considerations
Current Drug Discovery Technologies Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology